EC Clinical and Medical Case Reports

Dissecting the underlying cellular, molecular and genetic basis of inflammatory hypoxic tumor microenvironment in complex gastro-hepatic diseases especially colorectal carcinoma warrants dynamic timeline-driven evidence-based global collaborations in clinical research with eventual design of immuno-therapeutically safe patient-friendly cost-effective treatment modalities in the distressing Covid-19/Omicron pandemic era. A sophisticated “genetic blueprint” with emphasis on early risk-assessment, risk-stratification, diagnosis and immune-metabolic genetic subgrouping of early vs advanced tumor stage and grade of colorectal carcinoma is warranted for cost-effective gastro-hepatic disease management amongst genetically susceptible cohorts worldwide. The disproportionate share of morbidity and mortality amongst genetically and ethnically heterogeneous population-pools symptomatic of early vs advanced stage/grade colorectal tumors is certainly intriguing; public health-oriented clinical management endeavors for meaningful patient-centric evidence-based pragmatic outcomes for successful design and development of clinically validated biomarkers for colorectal management would prove to be a “gastro-hepatic carcinogenesis genetic roadmap” for patient-friendly immunotherapeutically safe precision medicine-oriented treatment.

1. Pandey S and Agrawal DK. “Immunobiology of Toll-like Receptors: Emerging trends”. Immunology and Cell Biology4 (2006): 333-341.
2. Pandey S., et al. “Recent advances in the immunobiology of Ceramide”. Experimental and Molecular Pathology 3 (2007): 298-309.
3. Pandey S. “Aldose Reductase inhibitor Fidarestat as a promising drug target in Autophagy-mediated Colorectal Carcinoma: a pilot study”. Asian Pacific Journal of Cancer Prevention12 (2015): 4981-4985.